Nasal Immunization with a Malaria Transmission-Blocking Vaccine Candidate, Pfs25, Induces Complete Protective Immunity in Mice against Field Isolates of Plasmodium falciparum
Open Access
- 1 November 2005
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 73 (11) , 7375-7380
- https://doi.org/10.1128/iai.73.11.7375-7380.2005
Abstract
Malaria transmission-blocking vaccines based on antigens expressed in sexual stages of the parasites are considered one promising strategy for malaria control. To investigate the feasibility of developing noninvasive mucosal transmission-blocking vaccines against Plasmodium falciparum , intranasal immunization experiments with Pichia pastoris -expressed recombinant Pfs25 proteins were conducted. Mice intranasally immunized with the Pfs25 proteins in the presence of a potent mucosal adjuvant cholera toxin induced robust systemic as well as mucosal antibodies. All mouse immunoglobulin G (IgG) subclasses except IgG3 were found in serum at comparable levels, suggesting that the immunization induced mixed Th1 and Th2 responses. Consistent with the expression patterns of the Pfs25 proteins in the parasites, the induced immune sera specifically recognized ookinetes but not gametocytes. In addition, the immune sera recognized Pfs25 proteins with the native conformation but not the denatured forms, indicating that mucosal immunization induced biologically active antibodies capable of recognizing conformational epitopes of native Pfs25 proteins. Feeding Anopheles dirus mosquitoes with a mixture of the mouse immune sera and gametocytemic blood derived from patients infected with P. falciparum resulted in complete interference with oocyst development in mosquito midguts. The observed transmission-blocking activities were strongly correlated with specific serum antibody titers. Our results demonstrated for the first time that a P. falciparum transmission-blocking vaccine candidate is effective against field-isolated parasites and may justify the investigation of noninvasive mucosal vaccination regimens for control of malaria, a prototypical mucosa-unrelated mosquito-borne parasitic disease.Keywords
This publication has 30 references indexed in Scilit:
- Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malariaVaccine, 2005
- Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28—evaluation of homologous and heterologous antigen-delivery prime-boost strategyVaccine, 2004
- Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticlesVaccine, 2004
- Induction of Plasmodium falciparum Transmission-Blocking Antibodies in Nonhuman Primates by a Combination of DNA and Protein ImmunizationsInfection and Immunity, 2004
- New generation of mucosal adjuvants for the induction of protective immunityReviews in Medical Virology, 2003
- Oral Immunization with a Recombinant Malaria Protein Induces Conformational Antibodies and Protects Mice against Lethal MalariaInfection and Immunity, 2003
- Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability ofPlasmodium vivaxTo Infect MosquitoesInfection and Immunity, 2000
- Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19 kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuated Salmonella vaccine strainsMicrobiology, 1999
- Intranasal immunization with yeast‐expressed 19 kD carboxyl‐terminal fragment of Plasmodium yoelii merozoite surface protein‐1 (yMSP119) induces protective immunity to blood stage malaria infection in miceParasite Immunology, 1998
- A vaccine candidate from the sexual stage of human malaria that contains EGF-like domainsNature, 1988